Department of Hepatology and Metabolic Center University Hospital Gasthuisberg Herestraat 49, 3000 Leuven, Belgium.
Curr Pharm Des. 2011;17(24):2550-7. doi: 10.2174/138161211797247596.
There are numerous inborn errors of metabolism of the liver, and they are all rare to very rare. To get a clear picture of the indications for gene transfer in these conditions, it is essential to get a clear view on the current (lack of) insight in the pathophysiology of these disorders, the current treatment options and hence on the window of opportunity for new treatments as gene transfer. The aim of this review, is to illustrate the problems related to treatment of inborn errors of metabolism of the liver. General aspects defining the quest for treatments for very rare diseases are touched upon, but for the sake of clarity, this review is restricted to five illustrative examples: Crigler-Najjar type I, the urea cycle defects, phenylketonuria, classic galactosemia and propionic acidemia. These examples reflect the problems that are currently experienced and can be expected, when gene transfer trials for these disorders are undertaken.
肝脏有许多先天性代谢错误,而且它们都非常罕见。为了清楚了解这些疾病中基因转移的适应症,必须清楚了解这些疾病的病理生理学、当前的治疗选择,以及作为基因转移的新治疗方法的机会窗口。本综述的目的是说明与肝脏先天性代谢错误的治疗相关的问题。本文涉及了确定治疗非常罕见疾病的治疗方法的一般方面,但为了清晰起见,本综述仅限于五个有说明性的例子:Crigler-Najjar 型 I、尿素循环缺陷、苯丙酮尿症、经典半乳糖血症和丙酸血症。这些例子反映了目前在进行这些疾病的基因转移试验时所遇到的和可以预期的问题。